The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of pembrolizumab monotherapy and in combination with BCR inhibitors for Richter transformation of chronic lymphocytic leukemia (CLL).
 
Yucai Wang
Employment - Merck (I)
Stock and Other Ownership Interests - Merck (I)
Honoraria - Kite, a Gilead company (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); BeiGene (Inst); Genmab (Inst); Incyte (Inst); Innocare (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Lilly (Inst); Loxo (Inst); TG Therapeutics (Inst)
Research Funding - Genentech (Inst); Genmab (Inst); Incyte (Inst); InnoCare (Inst); Loxo (Inst); MorphoSys (Inst); Novartis (Inst)
 
Betsy R. LaPlant
No Relationships to Disclose
 
Sameer Ashok Parikh
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Genentech (Inst); Janssen (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Merck (Inst); NovalGen (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
Research Funding - Ascentage Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Janssen (Inst); Merck (Inst); TG Therapeutics (Inst)
 
Jose Francisco Leis
No Relationships to Disclose
 
Timothy G. Call
No Relationships to Disclose
 
Tait D. Shanafelt
Research Funding - Celgene (Inst); Cephalon (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Hospira (Inst); Pharmacyclics (Inst); Polyphenon E International (Inst)
Patents, Royalties, Other Intellectual Property - Dr. Shanafelt is co-inventor of the Well-being Index Instruments (Physician Well-being Index; Nurse Well-being Index; Medical Student Well-being Index; Well-being Index) and the Mayo Clinic Participatory Management Leadership Index. Mayo Clinic holds the
Other Relationship - Medical Center
 
Rong He
No Relationships to Disclose
 
Ivana N. Micallef
No Relationships to Disclose
 
Grzegorz S. Nowakowski
Consulting or Advisory Role - Bantam Pharmaceutical; Celgene (Inst); Debiopharm Group; Genentech (Inst); Karyopharm Therapeutics; Kite/Gilead; kymera; MorphoSys (Inst); Ryvu Therapeutics; Selvita; TG Therapeutics
Research Funding - Celgene (Inst); MorphoSys (Inst); NanoString Technologies (Inst)
 
Thomas Matthew Habermann
Consulting or Advisory Role - Celgene; Kite/Gilead
Research Funding - Genentech (Inst)
(OPTIONAL) Uncompensated Relationships - BeiGene; Incyte; Loxo/Lilly; MorphoSys; Seagen; Tessa Therapeutics
 
Thomas E. Witzig
Honoraria - Curio Science (Inst)
Consulting or Advisory Role - Salarius Pharmaceuticals; Tornado Therapeutics
Research Funding - Acerta Pharma (Inst); Acrotech Biopharma (Inst); Celgene (Inst); Karyopharm Therapeutics (Inst); Kura Oncology (Inst)
Patents, Royalties, Other Intellectual Property - I am co-inventor on a patent application filed by Mayo Clinic and pending on the combination of CRM1 inhibitors with salicylates. Please note - simply filed - not even close to being granted. (Inst)
 
Amber B. Koehler
Consulting or Advisory Role - Abbvie (Inst); TG Therapeutics (Inst)
 
Paul Joseph Hampel
No Relationships to Disclose
 
Saad Kenderian
Consulting or Advisory Role - Kite/Gilead, Calibr, Luminary Therapeutics, Humanigen, Juno/BMS, Capstan Bio, and Novartis for Advisory Board. Torque, Calibr, Novartis, Capstan Bio, and Humanigen for Consultancy. (Inst)
Research Funding - Kite, Gilead, Juno, BMS, Novartis, Humanigen, MorphoSys, Tolero, Sunesis/Viracta, LifEngine Animal Health Laboratories Inc, and Lentigen. (Inst)
Patents, Royalties, Other Intellectual Property - Novartis, Humanigen, Mettaforge, MustangBio, Sendero. (Inst)
Other Relationship - Humanigen, Carisma, for DSMB. (Inst)
 
Eli Muchtar
No Relationships to Disclose
 
Casey N. Aitken
No Relationships to Disclose
 
Sutapa Sinha
No Relationships to Disclose
 
Neil E. Kay
Consulting or Advisory Role - Abbvie (Inst); Acerta Pharma/AstraZeneca (Inst); Agios (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CSL Behring (Inst); CytomX Therapeutics (Inst); DAAN Biotherapeutics (Inst); Dava Oncology (Inst); Genentech/Abbvie (Inst); Janssen Biotech (Inst); MEI Pharma (Inst); MorphoSys (Inst); Oncotracker (Inst); Pharmacyclics (Inst); Rigel (Inst); Sunesis Pharmaceuticals (Inst); Targeted Oncology (Inst); TG Therapeutics (Inst); Tolero Pharmaceuticals (Inst)
Research Funding - Abbvie; Acerta Pharma; Bristol-Myers Squibb; Celgene; Genentech; MEI Pharma; Pharmacyclics/Janssen; Sunesis Pharmaceuticals; TG Therapeutics; Tolero Pharmaceuticals
 
Stephen M. Ansell
Honoraria - Answers in CME; Medscape; Research to Practice; WebMD
Research Funding - ADC Therapeutics (Inst); Affimed Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst); Regeneron (Inst); Seagen (Inst); Step Pharma (Inst); Takeda (Inst)
 
Wei Ding
Consulting or Advisory Role - Alexion Pharmaceuticals (Inst); BeiGene (Inst); Merck (Inst); Octapharma USA (Inst)
Research Funding - Abbvie (Inst); AstraZeneca (Inst); BeiGene (Inst); DTRM (Inst); Merck (Inst); Octapharma USA (Inst)